Delafloxacin: design, development and potential place in therapy
Francisco Javier Candel, Marina Peñuelas Department of Clinical Microbiology and Infectious Diseases, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Universidad Complutense, Madrid, Spain Abstract: Delafloxacin (DLX) is a new...
Main Authors: | Candel FJ, Peñuelas M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-03-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/delafloxacin-design-development-and-potential-place-in-therapy-peer-reviewed-article-DDDT |
Similar Items
-
Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
by: Righi E, et al.
Published: (2018-04-01) -
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis
by: Ioanna Vlachaki, et al.
Published: (2021-10-01) -
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial
by: Sandra McCurdy, et al.
Published: (2020-08-01) -
Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand?
by: Neeta D Gade, et al.
Published: (2013-07-01) -
Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
by: Louiselle LeBlanc, et al.
Published: (2006-09-01)